|
1
|
Wolfgang CL, Herman JM, Laheru DA, Klein
AP, Erdek MA, Fishman EK and Hruban RH: Recent progress in
pancreatic cancer. CA Cancer J Clin. 63:318–348. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohno K, Nishimori H, Yasoshima T,
Kamiguchi K, Hata F, Fukui R, Okuya K, Kimura Y, Denno R, Kon S, et
al: Inhibition of osteopontin reduces liver metastasis of human
pancreatic cancer xenografts injected into the spleen in a mouse
model. Surg Today. 40:347–356. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kunnimalaiyaan S, Trevino J, Tsai S,
Gamblin TC and Kunnimalaiyaan M: Xanthohumol-mediated suppression
of Notch1 signaling is associated with antitumor activity in human
pancreatic cancer cells. Mol Cancer Ther. 14:1395–1403. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maupin KA, Sinha A, Eugster E, Miller J,
Ross J, Paulino V, Keshamouni VG, Tran N, Berens M, Webb C, et al:
Glycogene expression alterations associated with pancreatic cancer
epithelial-mesenchymal transition in complementary model systems.
PLoS One. 5:e130022010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hotz B, Arndt M, Dullat S, Bhargava S,
Buhr HJ and Hotz HG: Epithelial to mesenchymal transition:
Expression of the regulators snail, slug, and twist in pancreatic
cancer. Clin Cancer Res. 13:4769–4776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sabbah M, Emami S, Redeuilh G, Julien S,
Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O and Gespach C:
Molecular signature and therapeutic perspective of the
epithelial-to-mesen-chymal transitions in epithelial cancers. Drug
Resist Updat. 11:123–151. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Buck E, Eyzaguirre A, Barr S, Thompson S,
Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P and Haley JD:
Loss of homotypic cell adhesion by epithelial-mesenchymal
transition or mutation limits sensitivity to epidermal growth
factor receptor inhibition. Mol Cancer Ther. 6:532–541. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thomson S, Buck E, Petti F, Griffin G,
Brown E, Ramnarine N, Iwata KK, Gibson N and Haley JD: Epithelial
to mesenchymal transition is a determinant of sensitivity of
non-small-cell lung carcinoma cell lines and xenografts to
epidermal growth factor receptor inhibition. Cancer Res.
65:9455–9462. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hruban RH and Adsay NV: Molecular
classification of neoplasms of the pancreas. Hum Pathol.
40:612–623. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gutt R, Liauw SL and Weichselbaum RR: The
role of radiotherapy in locally advanced pancreatic carcinoma. Nat
Rev Gastroenterol Hepatol. 7:437–447. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shen Y, Pan Y, Xu L, Chen L, Liu L, Chen
H, Chen Z and Meng Z: Identifying microRNA-mRNA regulatory network
in gemcitabine-resistant cells derived from human pancreatic cancer
cells. Tumour Biol. 36:4525–4534. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang XJ, Ye H, Zeng CW, He B, Zhang H and
Chen YQ: Dysregulation of miR-15a and miR-214 in human pancreatic
cancer. J Hematol Oncol. 3:462010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Budhu A, Ji J and Wang XW: The clinical
potential of microRNAs. J Hematol Oncol. 3:372010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim WK, Park M, Kim YK, Tae YK, Yang HK,
Lee JM and Kim H: MicroRNA-494 downregulates KIT and inhibits
gastrointestinal stromal tumor cell proliferation. Clin Cancer Res.
17:7584–7594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ohdaira H, Sekiguchi M, Miyata K and
Yoshida K: MicroRNA-494 suppresses cell proliferation and induces
senescence in A549 lung cancer cells. Cell Prolif. 45:32–38. 2012.
View Article : Google Scholar
|
|
20
|
Parimon T, Brauer R, Schlesinger SY, Xie
T, Jiang D, Ge L, Huang Y, Birkland TP, Parks WC, Habiel DM, et al:
Syndecan-1 controls lung tumorigenesis by regulating miRNAs
packaged in exosomes. Am J Pathol. 188:1094–1103. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gharbaran R: Advances in the molecular
functions of syndecan-1 (SDC1/CD138) in the pathogenesis of
malignancies. Crit Rev Oncol Hematol. 94:1–17. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Akl MR, Nagpal P, Ayoub NM, Prabhu SA,
Gliksman M, Tai B, Hatipoglu A, Goy A and Suh KS: Molecular and
clinical profiles of syndecan-1 in solid and hematological cancer
for prognosis and precision medicine. Oncotarget. 6:28693–28715.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hashimoto Y, Skacel M and Adams JC:
Association of loss of epithelial syndecan-1 with stage and local
metastasis of colorectal adenocarcinomas: An immunohistochemical
study of clinically annotated tumors. BMC Cancer. 8:1852008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lundin M, Nordling S, Lundin J, Isola J,
Wiksten JP and Haglund C: Epithelial syndecan-1 expression is
associated with stage and grade in colorectal cancer. Oncology.
68:306–313. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee SH, Choi EJ, Kim MS, Park JW, Lee YS,
Kim SY and Kang CS: Prognostic significance of syndecan-1
expression in squamous cell carcinoma of the tonsil. Int J Clin
Oncol. 19:247–253. 2014. View Article : Google Scholar
|
|
26
|
Lendorf ME, Manon-Jensen T, Kronqvist P,
Multhaupt HA and Couchman JR: Syndecan-1 and syndecan-4 are
independent indicators in breast carcinoma. J Histochem Cytochem.
59:615–629. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kusumoto T, Kodama J, Seki N, Nakamura K,
Hongo A and Hiramatsu Y: Clinical significance of syndecan-1 and
versican expression in human epithelial ovarian cancer. Oncol Rep.
23:917–925. 2010.PubMed/NCBI
|
|
28
|
Ma Y, Wu Q, Li X, Gu X, Xu J and Yang J:
Pancreatic cancer: From bench to bedside. Ann Transl Med.
4:4582016. View Article : Google Scholar
|
|
29
|
Qian CN, Furge KA, Knol J, Huang D, Chen
J, Dykema KJ, Kort EJ, Massie A, Khoo SK, Vanden Beldt K, et al:
Activation of the PI3K/AKT pathway induces urothelial carcinoma of
the renal pelvis: Identification in human tumors and confirmation
in animal models. Cancer Res. 69:8256–8264. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhu HN, Zhang SZ, Zhou YK, Wang CL and Wu
XB: Cloning and sequence analysis of the coding sequence of β-actin
cDNA from the Chinese alligator and suitable internal reference
primers from the β-actin gene. Genet Mol Res. 14:12159–12167. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
32
|
Michl P and Gress TM: Current concepts and
novel targets in advanced pancreatic cancer. Gut. 62:317–326. 2013.
View Article : Google Scholar
|
|
33
|
Saleem M, Kaur S, Kweon MH, Adhami VM,
Afaq F and Mukhtar H: Lupeol, a fruit and vegetable based
triterpene, induces apoptotic death of human pancreatic
adenocarcinoma cells via inhibition of Ras signaling pathway.
Carcinogenesis. 26:1956–1964. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
He W, Li Y, Chen X, Lu L, Tang B, Wang Z,
Pan Y, Cai S, He Y and Ke Z: miR-494 acts as an anti-oncogene in
gastric carcinoma by targeting c-myc. J Gastroenterol Hepatol.
29:1427–1434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Libório-Kimura TN, Jung HM and Chan EK:
miR-494 represses HOXA10 expression and inhibits cell proliferation
in oral cancer. Oral Oncol. 51:151–157. 2015. View Article : Google Scholar
|
|
36
|
Ma YB, Li GX, Hu JX, Liu X and Shi BM:
Correlation of miR-494 expression with tumor progression and
patient survival in pancreatic cancer. Genet Mol Res.
14:18153–18159. 2015. View Article : Google Scholar
|
|
37
|
Szarvas T, Reis H, Vom Dorp F,
Tschirdewahn S, Niedworok C, Nyirady P, Schmid KW, Rübben H and
Kovalszky I: Soluble syndecan-1 (SDC1) serum level as an
independent pre-operative predictor of cancer-specific survival in
prostate cancer. Prostate. 76:977–985. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kim SY, Choi EJ, Yun JA, Jung ES, Oh ST,
Kim JG, Kang WK and Lee SH: Syndecan-1 expression is associated
with tumor size and EGFR expression in colorectal carcinoma: A
clinicopathological study of 230 cases. Int J Med Sci. 12:92–99.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lang SH, Hyde C, Reid IN, Hitchcock IS,
Hart CA, Bryden AA, Villette JM, Stower MJ and Maitland NJ:
Enhanced expression of vimentin in motile prostate cell lines and
in poorly differentiated and metastatic prostate carcinoma.
Prostate. 52:253–263. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhao Y, Yan Q, Long X, Chen X and Wang Y:
Vimentin affects the mobility and invasiveness of prostate cancer
cells. Cell Biochem Funct. 26:571–577. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Javle MM, Gibbs JF, Iwata KK, Pak Y,
Rutledge P, Yu J, Black JD, Tan D and Khoury T:
Epithelial-mesenchymal transition (EMT) and activated extracellular
signal-regulated kinase (p-Erk) in surgically resected pancreatic
cancer. Ann Surg Oncol. 14:3527–3533. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Oida Y, Yamazaki H, Tobita K, Mukai M,
Ohtani Y, Miyazaki N, Abe Y, Imaizumi T, Makuuchi H, Ueyama Y, et
al: Increased S100A4 expression combined with decreased E-cadherin
expression predicts a poor outcome of patients with pancreatic
cancer. Oncol Rep. 16:457–463. 2006.PubMed/NCBI
|
|
45
|
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada
M, Koizumi M, Tulachan SS, Ito D, Kami K, Mori T, et al: N-cadherin
expression and epithelial-mesenchymal transition in pancreatic
carcinoma. Clin Cancer Res. 10:4125–4133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Song L, Liu D, Wang B, He J, Zhang S, Dai
Z, Ma X and Wang X: miR-494 suppresses the progression of breast
cancer in vitro by targeting CXCR4 through the Wnt/β-catenin
signaling pathway. Oncol Rep. 34:525–531. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Jang B, Jung H, Chung H, Moon BI and Oh
ES: Syndecan-2 enhances E-cadherin shedding and fibroblast-like
morphological changes by inducing MMP-7 expression in colon cancer
cells. Biochem Biophys Res Commun. 477:47–53. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu Y, Li X, Zhu S, Zhang JG, Yang M, Qin
Q, Deng SC, Wang B, Tian K, Liu L, et al: Ectopic expression of
miR-494 inhibited the proliferation, invasion and chemoresistance
of pancreatic cancer by regulating SIRT1 and c-Myc. Gene Ther.
22:729–738. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhan MN, Yu XT, Tang J, Zhou CX, Wang CL,
Yin QQ, Gong XF, He M, He JR, Chen GQ, et al: MicroRNA-494 inhibits
breast cancer progression by directly targeting PAK1. Cell Death
Dis. 8:e25292017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yun S, Kim WK, Kwon Y, Jang M, Bauer S and
Kim H: Survivin is a novel transcription regulator of KIT and is
downregulated by miRNA-494 in gastrointestinal stromal tumors. Int
J Cancer. 142:2080–2093. 2018. View Article : Google Scholar :
|
|
51
|
Romano G, Acunzo M, Garofalo M, Di Leva G,
Cascione L, Zanca C, Bolon B, Condorelli G and Croce CM: MiR-494 is
regulated by ERK1/2 and modulates TRAIL-induced apoptosis in
non-small-cell lung cancer through BIM down-regulation. Proc Natl
Acad Sci USA. 109:16570–16575. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liu K, Liu S, Zhang W, Jia B, Tan L, Jin Z
and Liu Y: miR-494 promotes cell proliferation, migration and
invasion, and increased sorafenib resistance in hepatocellular
carcinoma by targeting PTEN. Oncol Rep. 34:1003–1010. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li L, Li Z, Kong X, Xie D, Jia Z, Jiang W,
Cui J, Du Y, Wei D, Huang S, et al: Down-regulation of microRNA-494
via loss of SMAD4 increases FOXM1 and beta-catenin signaling in
pancreatic ductal adenocarcinoma cells. Gastroenterology.
147:485–497.e418. 2014. View Article : Google Scholar
|
